Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Equity-to-Asset : -0.55 (As of Dec. 2018)

View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Parnell Pharmaceuticals Holdings's Total Stockholders Equity for the quarter that ended in Dec. 2018 was $-13.28 Mil. Parnell Pharmaceuticals Holdings's Total Assets for the quarter that ended in Dec. 2018 was $24.00 Mil. Therefore, Parnell Pharmaceuticals Holdings's Equity to Asset Ratio for the quarter that ended in Dec. 2018 was -0.55.

The historical rank and industry rank for Parnell Pharmaceuticals Holdings's Equity-to-Asset or its related term are showing as below:

PARNF's Equity-to-Asset is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.58
* Ranked among companies with meaningful Equity-to-Asset only.

Parnell Pharmaceuticals Holdings Equity-to-Asset Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnell Pharmaceuticals Holdings Equity-to-Asset Chart

Parnell Pharmaceuticals Holdings Annual Data

Trend

Jun12

Jun13

Jun14

Dec15

Dec16

Dec17

Dec18

Equity-to-Asset

Get a 7-Day Free Trial

0.77

0.44

0.17

-0.38

-0.55

Parnell Pharmaceuticals Holdings Semi-Annual Data
	Jun12	Jun13	Jun14	Dec15	Dec16	Dec17	Dec18
Equity-to-Asset	Get a 7-Day Free Trial			0.77	0.44	0.17	-0.38	-0.55

Competitive Comparison of Parnell Pharmaceuticals Holdings's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Parnell Pharmaceuticals Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Parnell Pharmaceuticals Holdings's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parnell Pharmaceuticals Holdings's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Parnell Pharmaceuticals Holdings's Equity-to-Asset falls into.

Parnell Pharmaceuticals Holdings Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Parnell Pharmaceuticals Holdings's Equity to Asset Ratio for the fiscal year that ended in Dec. 2018 is calculated as

Equity to Asset (A: Dec. 2018 )	=	Total Stockholders Equity	/	Total Assets
	=	-13.282	/	24.003
	=	-0.55

Parnell Pharmaceuticals Holdings's Equity to Asset Ratio for the quarter that ended in Dec. 2018 is calculated as

Equity to Asset (Q: Dec. 2018 )	=	Total Stockholders Equity	/	Total Assets
	=	-13.282	/	24.003
	=	-0.55

Parnell Pharmaceuticals Holdings (OTCPK:PARNF) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Parnell Pharmaceuticals Holdings Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Parnell Pharmaceuticals Holdings's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015

Website

https://www.parnell.com

Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.